HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

AbstractBACKGROUND:
The critical analysis of baseline factors has been found to be useful to predict virologic nonresponse (NR), relapse, or sustained virologic response (SVR) in patients infected with hepatitis C virus (HCV) who receive antiviral therapy. In the present retrospective study we tried to find out whether gamma-glutamyltranspeptidase (GGT) may be one of the baseline factors which are of special predictive power. We analyzed, in patients with different treatment outcomes, the predictive power of established baseline factors either in combination with GGT or by evaluating the predictive value of GGT independently.
METHODS:
Individual data from 632 patients chronically infected with HCV type 1 (n = 561) or type 2/3 (n = 71) were analyzed. All patients had received their first course of antiviral therapy and were treated with pegylated interferon α-2a or -2b plus ribavirin.
RESULTS:
In patients with HCV type 1, a multivariate multinomial logistic regression analysis identified low GGT (p < 0.0001), high cholesterol (p < 0.0001), age ≤ 40 years (p < 0.0001), high alanine aminotransferase (p = 0.0006), low viremia (p = 0.0014), and absence of cirrhosis (p = 0.0164) as independent predictors. While these baseline factors heralded improved virologic response, high GGT, in contrast, was significantly associated with NR (p < 0.0001). A strong correlation was found between log(10) GGT and a scoring variable S (r = -0.26 for prediction of SVR, p < 0.001; r = 0.11 for prediction of NR, p = 0.016) summarizing predictive information from other baseline factors.
CONCLUSIONS:
These findings prove the predictive sensitivity of GGT as an independent indicator of nonresponsiveness even at levels that are slightly above the normal range. This new predictive parameter may help to improve individualized therapy in HCV type-1 infection.
AuthorsViola Weich, Eva Herrmann, Tje Lin Chung, Christoph Sarrazin, Holger Hinrichsen, Peter Buggisch, Tilman Gerlach, Hartwig Klinker, Ulrich Spengler, Alexandra Bergk, Stefan Zeuzem, Thomas Berg
JournalJournal of gastroenterology (J Gastroenterol) Vol. 46 Issue 12 Pg. 1427-36 (Dec 2011) ISSN: 1435-5922 [Electronic] Japan
PMID21912897 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • gamma-Glutamyltransferase
  • peginterferon alfa-2b
  • peginterferon alfa-2a
Topics
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents (administration & dosage, therapeutic use)
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic (drug therapy, virology)
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (administration & dosage, therapeutic use)
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Polyethylene Glycols (administration & dosage, therapeutic use)
  • Predictive Value of Tests
  • Recombinant Proteins (administration & dosage, therapeutic use)
  • Reproducibility of Results
  • Retrospective Studies
  • Ribavirin (administration & dosage, therapeutic use)
  • Treatment Outcome
  • Young Adult
  • gamma-Glutamyltransferase (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: